Condition
Active Cancer
Total Trials
5
Recruiting
2
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
Early P 1 (1)
P 4 (1)
Trial Status
Completed2
Recruiting2
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07852637Phase 4Not Yet Recruiting
Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism
NCT07819526Recruiting
Acute Ischemic Stroke in Patients With Active Cancer
NCT07608848Early Phase 1Recruiting
First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer
NCT05403801Not ApplicableCompletedPrimary
STAMP+CBT mHealth for Cancer Pain
NCT02212496Completed
Identification the Cause of Cerebral Infarction in Patients With Cancer
Showing all 5 trials